Nejm01.04.21 Antidiabéticos para reducir el RCV en DM2. MPR 25.03 SGLT2 Inhibitor Use Linked to Reduced Risk of Atrial Arrhythmias in T2DM Patients. Jama rubino 23.03.21 Semaglutida y pérdida de peso.
Jamainternal lam 08.02.21 Prediabetes. Bmj 13.01.21 aGLP1 y gliflozinas RS y MA. Dapagliflozin Under Review for Chronic Kidney Disease. The Food and Drug Administration (FDA) has granted Priority Review to dapagliflozin (Farxiga; AstraZeneca) for the treatment of new or worsening chronic kidney disease (CKD) in adults with and without type 2 diabetes (T2D).
The regulatory submission includes data from the phase 3 DAPA-CKD trial, which was stopped early in March 2020 due to “overwhelming efficacy”. The multicenter, event-driven, double-blind, placebo-controlled trial compared the effect of dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, to placebo on renal outcomes and cardiovascular (CV) mortality in patients with CKD (N=4304).
Patients were randomized 1:1 to receive either dapagliflozin (5mg or 10mg) once daily or placebo in addition to standard of care. Study findings showed that dapagliflozin reduced the composite measure of worsening of renal function or risk of CV or renal death by 39% compared with placebo (absolute risk reduction [ARR] 5.3%; P <.0001). Reference. ADA 2021 Standard of care. INFAC 2021 aGLP-1 perfil CV. Saxenda Approved for Obesity in Adolescent Patients MPR.
MPR 04.12. Canagliflozin Beneficial Even for Advanced Kidney Disease posthoc Credence. INFAC Vol 28 4 Nuevas evidencias Gliflozinas 2020. Mescape 18.11 sotagliflozina. Nejmo Finerenona en DM y ERC. Nejme 2020 Finerenonaa editorial. FMC Oct 2020 Utilidad Gliflozinas. Strategy Diabetes Quality Prescribing for Diabetes 2018. OSU Sept Resultados CV de los nuevos AD. Circulation 220 AHA Statement Protección cardiorrenal con los nuevos AD. MPR 24.09 Metformin May Slow Cognitive Decline in Seniors With T2DM MPR. BMJ 2020 Gliflozinas y eventos CV cohortes. Dapagliflozina en ERC NEJM 2020. Resumen ADA 2020. ECA Ertugliflozina NEJM 2020. MTRAC SGLT2 inhibitors for type 2 diabetes final public extract. BMJ 23.09 Gliflozinas vs iDPP4 y reducción riesgo CV. Diab Metab 2020 Eplerenona a altas dosis en DM y alto ECV: mejora cociente alb-cr Data from the MIRAD trial. Outline AbstractKeywordsIntroductionMaterials and methodsResultsDiscussionLimitationsConclusionAuthors’ contributionsRole of fundingConflicts of interestAppendix A.
Supplementary dataReferences Abstract Aim. Ann Intern Med figure 1 glucose lowering medication in type 2 diabetes overall approach. Ann Intern Med 09.20 appendix figure drug specific and patient factors to consider when selecting antihype. Ann Intern Med 09.2020 Actualización ADA tto DM2. MPR 26.08.20. Boxed Warning Removed From Canagliflozin Labeling. BMJ agosto 20 canagliflozina y amputación. Invokana, Invokamet, Invokamet XR (canagliflozin): MedWatch Safety Alert - Boxed Warning about Risk of Leg and Foot Amputations Removed.
[Posted 08/26/2020] AUDIENCE: Patient, Health Professional, Endocrinology, Pharmacy ISSUE: Based on FDA's review of new data from three clinical trials, the boxed warning about amputation risk from the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) was removed from the prescribing information.
FDA reviews of new clinical trial data demonstrated additional heart- and kidney-related benefits, which led to additional approved uses. Specifically, in 2018, canagliflozin was approved to reduce the risk of major heart-related events such as heart attack, stroke, or death in patients with type 2 diabetes who have known heart disease; and, in 2019, it was approved to reduce the risk of end-stage kidney disease, worsening of kidney function, heart-related death, and being hospitalized for heart failure in certain patients with type 2 diabetes and diabetic kidney disease.
JACC Agosto Panel de expertos recomendación de nuevos antidiabéticos. aGL1 más gliflozinas 2020. Medscape aGLP1 mejoran resultados CV 2020. Ann Intern Med 2020 Antidiabéticos Editorial. Ann Intern Med 2020 RS y MA en red antidiabéticos. CIRCULATION 2020 subestudio COMPASS ACO AAG vs AAG DM. Jamacardiology honigberg 2020 junio a GLP1. DM y SU 2020. Ficha Osakidetza Semaglutida es. Crtitica publicidad semaglutida definitiva. OSU Mayo 2020 Insulina NPH. BMJ 28.04 Gliflozinas y efectos renales Scandinavian cohorte study. BMJ 29.04 Gliflozinas vs iDPP4 renal Editorial. JAMA Newt Open intensificación tto DM alta 24. BMJ Gliflozinas vs iDPP4 Observacional riesgo renal 29. BMJ Ed. Gliflozinas protección renal 29.04.20. Steven M Smith, assistant professor of pharmacyAuthor affiliationsssmith@cop.ufl.edu Observational data from clinical practice favour these drugs over DPP4 inhibitors Chronic kidney disease affects 700 million individuals worldwide and contributes to one in 20 deaths annually.1 Globally, the age standardised mortality rate attributable to CKD has remained virtually unchanged over the past decade, in contrast to most other non-communicable chronic diseases for which these rates have fallen.12 This seemingly intractable problem is driven largely by diabetes.1 It is thus not surprising that sodium glucose cotransporter 2 (SGLT2) inhibitors have garnered considerable attention following recent clinical trials showing consistent benefits of these glucose lowering drugs on major adverse kidney outcomes.3456 Taken together, current evidence strongly suggests a role for SGLT2 inhibitors in people with or at risk of chronic kidney disease.
AHRQ Patient Safety diabetes abril 2020. MPR Dapagliflozin CKD Trial Stopped Early Due to “Overwhelming Efficacy” JAMA Gliflozinas editorial 27 march. MPR 18.03 Suspensión temporal gliflozinas previa a cirugía. MTRAC SGLT2 inhibitors for type 2 diabetes final public extract Jan 2020. Evidencia en DM Editorial Lancet Diab. Antidiabéticos y resultados CV TABLA Zhu J.
Comentario Zhu J Lancet Diab. Zhu J Antidiabéticos y resultados CV Lancet Diab. Guía de gliflozinas para cardiólogos JACC HF 2020. Top5 diabetes highlights fron 2019 Medscape. Top5 diabetes highlights fron 2019 Medscape. NEJM Journal Watch: Summaries of and commentary on original medical and scientific articles from key medical journals. Allan S.
Brett, MD Glimepiride, in particular, does not appear to confer excess risk for adverse cardiovascular outcomes. Prescribing of sulfonylureas, generally as add-on therapy when metformin alone does not achieve adequate glycemic control in patients with type 2 diabetes, has been decreasing in recent years (PLoS One 2019; 14:e0221174). This trend likely reflects two major developments: First, newer agents — in particular, the dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists — are marketed heavily by the pharmaceutical industry to physicians and advertised directly to consumers.
And second, longstanding concern about the cardiovascular (CV) safety of sulfonylureas has gained traction. However, sulfonylureas are very inexpensive — a nontrivial consideration, given the extremely high price of most alternatives. Riddle makes two other important points. Gliflozinas y daño renal agudo RS 2019. ADASoCtto. ADA 2020 Standars of care Tto. ADA 2020 Standards of care summary. Medscape ADA recomienda nuevos AD. Medscape DM control glucémico en ancianos. Medicamentos a interrumpir DM. Glimepirida Diabetes Care 19. Oup accepted manuscript 2019.
Mannucci2019 a GLP1 MA. Sulfonilureas. DAPA HF edad Circulation19. Mc Murray NEJM19 DAPA HF. 'Best in Class' Diabetes Drugs Compared in Head-to-Head Trial. Oral semaglutide (Rybelsus, Novo Nordisk) lowered hemoglobin A1c more than empagliflozin (Jardiance, Boehringer Ingelheim/Lilly) in a recently published open-label, head-to-head comparison of the type 2 diabetes drugs.
The findings from the PIONEER-2 trial were published online in Diabetes Care. Semaglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist, has been available as a once-weekly subcutaneous injectable since December 2017; the oral version, the first tablet form of a GLP-1 agonist, was approved by the US Food and Drug Administration in September. Empagliflozin is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor that has been on the market since 2015. Helena W. Rodbard, MD, medical director of Endocrine and Metabolic Consultants, Rockville, Maryland, and colleagues compared the effects of the two agents on A1c and body weight at 26 and 52 weeks among patients with type 2 diabetes in the Novo Nordisk funded study. No CV Efficacy Data for Semaglutide.
10.2337@dc19 0883. Men2019 lixisenatida RA. Kristensen2019 aGLP1. Zuo2019 Ahorradores de potasio e IECA ARAII en nefropatía diabética. Tablas CV trials kidney HF web. Algoritmo SEMI 2019. Rosenstock JAMA19 CAROLINA Linagliptina vs glimepirida. DAPA HF Diapositivas ESCSep19. Gliflozinas en cardiología MedscapeSep19. Guía europea DM ESC Sep19. 2019 CADIME BTA Seguridad CV antidiabeticos no insulinicos. 2019 NICE Type 2 diabetes in adults management. Manejo hiperglucemia fcos no insulínicos DM2 AP 2019. Insulinas en DM BIT 2019. Reduciendo intensidad tratamiento en mayores con DM 2019.
Medscape 19 Gliflozinas seguridad. Scientific statement DM e IC AHA. Nejmoa1811744 appendix CREDENCE. REWIND Dulaglutida 2019. Medscape cambios ADA post CREDENCE print. Cambios ADA Post CREDENCE. ADA Guidance for the Screening and Management of CVD in Diabetes Clinical Advisor. Protección renal en DM Lancet Diab Endocrol.